vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Sprout Social, Inc. (SPT). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $120.9M, roughly 1.5× Sprout Social, Inc.). On growth, Sprout Social, Inc. posted the faster year-over-year revenue change (12.9% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $9.9M). Over the past eight quarters, Sprout Social, Inc.'s revenue compounded faster (11.8% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Sprout Social, Inc. is a technology company that runs a social media management platform. A public company headquartered in Chicago, it was founded in 2010 by Justyn Howard, Aaron Rankin, Gil Lara, and Peter Soung.
AMPH vs SPT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $120.9M |
| Net Profit | $24.4M | — |
| Gross Margin | 46.8% | 77.6% |
| Operating Margin | 19.4% | -9.0% |
| Net Margin | 13.3% | — |
| Revenue YoY | -1.8% | 12.9% |
| Net Profit YoY | -35.7% | — |
| EPS (diluted) | $0.51 | $-0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $120.9M | ||
| Q3 25 | $191.8M | $115.6M | ||
| Q2 25 | $174.4M | $111.8M | ||
| Q1 25 | $170.5M | $109.3M | ||
| Q4 24 | $186.5M | $107.1M | ||
| Q3 24 | $191.2M | $102.6M | ||
| Q2 24 | $182.4M | $99.4M | ||
| Q1 24 | $171.8M | $96.8M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $-9.4M | ||
| Q2 25 | $31.0M | $-12.0M | ||
| Q1 25 | $25.3M | $-11.2M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $-17.1M | ||
| Q2 24 | $37.9M | $-16.9M | ||
| Q1 24 | $43.2M | $-13.6M |
| Q4 25 | 46.8% | 77.6% | ||
| Q3 25 | 51.4% | 77.7% | ||
| Q2 25 | 49.6% | 77.7% | ||
| Q1 25 | 50.0% | 77.3% | ||
| Q4 24 | 46.5% | 78.1% | ||
| Q3 24 | 53.3% | 77.4% | ||
| Q2 24 | 52.2% | 77.5% | ||
| Q1 24 | 52.4% | 76.8% |
| Q4 25 | 19.4% | -9.0% | ||
| Q3 25 | 13.2% | -7.9% | ||
| Q2 25 | 24.2% | -11.0% | ||
| Q1 25 | 21.9% | -10.2% | ||
| Q4 24 | 24.2% | -12.8% | ||
| Q3 24 | 29.8% | -16.4% | ||
| Q2 24 | 30.3% | -16.6% | ||
| Q1 24 | 27.9% | -13.7% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | -8.1% | ||
| Q2 25 | 17.8% | -10.7% | ||
| Q1 25 | 14.8% | -10.3% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | -16.6% | ||
| Q2 24 | 20.8% | -17.0% | ||
| Q1 24 | 25.1% | -14.0% |
| Q4 25 | $0.51 | $-0.18 | ||
| Q3 25 | $0.37 | $-0.16 | ||
| Q2 25 | $0.64 | $-0.21 | ||
| Q1 25 | $0.51 | $-0.19 | ||
| Q4 24 | $0.74 | $-0.25 | ||
| Q3 24 | $0.78 | $-0.30 | ||
| Q2 24 | $0.73 | $-0.30 | ||
| Q1 24 | $0.81 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $95.3M |
| Total DebtLower is stronger | $608.7M | $40.0M |
| Stockholders' EquityBook value | $788.8M | $203.4M |
| Total Assets | $1.6B | $523.1M |
| Debt / EquityLower = less leverage | 0.77× | 0.20× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $95.3M | ||
| Q3 25 | $276.2M | $90.6M | ||
| Q2 25 | $231.8M | $101.5M | ||
| Q1 25 | $236.9M | $100.9M | ||
| Q4 24 | $221.6M | $86.4M | ||
| Q3 24 | $250.5M | $82.9M | ||
| Q2 24 | $217.8M | $80.9M | ||
| Q1 24 | $289.6M | $69.2M |
| Q4 25 | $608.7M | $40.0M | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $25.0M | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $203.4M | ||
| Q3 25 | $776.7M | $194.1M | ||
| Q2 25 | $757.5M | $184.6M | ||
| Q1 25 | $751.3M | $175.3M | ||
| Q4 24 | $732.3M | $166.6M | ||
| Q3 24 | $727.7M | $158.1M | ||
| Q2 24 | $713.3M | $152.1M | ||
| Q1 24 | $672.4M | $147.3M |
| Q4 25 | $1.6B | $523.1M | ||
| Q3 25 | $1.7B | $481.4M | ||
| Q2 25 | $1.6B | $422.9M | ||
| Q1 25 | $1.6B | $424.7M | ||
| Q4 24 | $1.6B | $428.3M | ||
| Q3 24 | $1.5B | $388.8M | ||
| Q2 24 | $1.5B | $393.6M | ||
| Q1 24 | $1.6B | $389.9M |
| Q4 25 | 0.77× | 0.20× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 0.15× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $10.9M |
| Free Cash FlowOCF − Capex | $24.6M | $9.9M |
| FCF MarginFCF / Revenue | 13.4% | 8.2% |
| Capex IntensityCapex / Revenue | 4.5% | 0.9% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $39.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $10.9M | ||
| Q3 25 | $52.6M | $9.3M | ||
| Q2 25 | $35.6M | $5.1M | ||
| Q1 25 | $35.1M | $18.1M | ||
| Q4 24 | $29.0M | $4.1M | ||
| Q3 24 | $60.0M | $9.0M | ||
| Q2 24 | $69.1M | $2.1M | ||
| Q1 24 | $55.3M | $11.2M |
| Q4 25 | $24.6M | $9.9M | ||
| Q3 25 | $47.2M | $8.5M | ||
| Q2 25 | $25.0M | $4.2M | ||
| Q1 25 | $24.4M | $16.7M | ||
| Q4 24 | $16.6M | $3.3M | ||
| Q3 24 | $46.2M | $8.5M | ||
| Q2 24 | $63.1M | $1.6M | ||
| Q1 24 | $46.5M | $10.1M |
| Q4 25 | 13.4% | 8.2% | ||
| Q3 25 | 24.6% | 7.4% | ||
| Q2 25 | 14.3% | 3.7% | ||
| Q1 25 | 14.3% | 15.3% | ||
| Q4 24 | 8.9% | 3.0% | ||
| Q3 24 | 24.1% | 8.3% | ||
| Q2 24 | 34.6% | 1.6% | ||
| Q1 24 | 27.1% | 10.4% |
| Q4 25 | 4.5% | 0.9% | ||
| Q3 25 | 2.8% | 0.7% | ||
| Q2 25 | 6.1% | 0.8% | ||
| Q1 25 | 6.3% | 1.2% | ||
| Q4 24 | 6.7% | 0.8% | ||
| Q3 24 | 7.2% | 0.5% | ||
| Q2 24 | 3.3% | 0.5% | ||
| Q1 24 | 5.1% | 1.1% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SPT
Segment breakdown not available.
